title: Plasma AGE-peptides and C-peptide in early-stage diabetic nephropathy patients on thiamine and pyridoxine therapy.
abstract: OBJECTIVE
  The aim of the study was to evaluate circulatory AGE-peptide levels in diabetic nephropathy and to observe the effects of thiamine (vitamin B1) and pyridoxine (vitamin B6) therapy.
  
  
  METHODS
  Type 2 diabetic patients (N.=57) were divided into two groups as "with nephropathy" (N.=27) and "without nephropathy" (N.=30). Diabetic nephropathy patients were treated with either B6 (N.=12) (250 mg/day) or B1+B6 (N.=15) (250 mg/day, each) for five months. At the beginning and the end of the experimentation period, glucose, HbA1c, triglyceride, cholesterol, insulin, C-peptide, thiamine pyrophosphate, pyridoxal phosphate and AGE- peptides were measured.
  
  
  RESULTS
  AGE-peptides were higher in the diabetic group with nephropathy than without nephropathy (P=0.005). Within five months AGE-peptides increased in the diabetic group without nephropathy (P=0.042) but not in the group with nephropathy treated either with B1+B6 or B6. In B6 treated group a substantial decrease was observed in HbA1c (P=0.033). B1+B6 or B6 treatment both caused an increase in C-peptide (P=0.006, P=0.004).
  
  
  CONCLUSIONS
  Among the parameters measured, plasma AGE-peptides was the only parameter found to be higher in type 2 diabetes mellitus patients "with nephropathy" than "without nephropathy". However, patients with nephropathy treated with B1+B6 or B6 did not display any further increase in AGE-peptides within five months. Both of the treatments caused an increase in C-peptide.
authors: Department of Biochemistry, Istanbul University, Istanbul, Turkey.
authors: E
authors: E
authors: Cetin
authors: S
authors: S
authors: Civelek
authors: G
authors: G
authors: Andican
authors: F
authors: F
authors: Candan Polizzi
authors: V
authors: V
authors: Yumuk
authors: G
authors: G
authors: Burçak
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001786:Blood Glucose / Q000032:analysis; D002096:C-Peptide / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications; D003928:Diabetic Nephropathies / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D017127:Glycation End Products, Advanced / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011732:Pyridoxal Phosphate / Q000097:blood; D011736:Pyridoxine / Q000627:therapeutic use*; D013831:Thiamine / Q000627:therapeutic use*; D013835:Thiamine Pyrophosphate / Q000097:blood; D014280:Triglycerides / Q000097:blood; D014803:Vitamin B Complex / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D006442:Glycated Hemoglobin; D017127:Glycation End Products, Advanced; D011732:Pyridoxal Phosphate; D011736:Pyridoxine; D013831:Thiamine; D013835:Thiamine Pyrophosphate; D014280:Triglycerides; D014803:Vitamin B Complex